SOUTH SAN FRANCISCO, Calif., March 28 /PRNewswire/ -- diaDexus, Inc. announced today that it is one of the companies invited to present at the 13th annual “Future Leaders in the Biotech Industry” conference to be held March 30 in New York. Sponsored by BioCentury, BIO and Thomson Financial among others, the conference showcases companies that have been identified as best positioned to provide market leadership and fresh investment options.
diaDexus’ Chief Executive Officer, Patrick Plewman, will provide a corporate overview and highlight the commercial opportunity for its PLAC(R) Test, the first and only blood test approved by the FDA to aid in predicting risk for ischemic stroke associated with atherosclerosis.
The diaDexus presentation will be held in Room 404/405 from 3:00-3:25 p.m. at the Millennium Broadway Hotel, New York. Investment professionals are invited to attend.
About diaDexus
diaDexus, Inc., a privately held biotechnology company based in South San Francisco, California, is focused on the discovery, development and commercialization of novel, patent-protected diagnostic products with high clinical value. The PLAC(R) test, developed by diaDexus, Inc., is a blood test cleared by the U.S. Food and Drug Administration to aid in the prediction of an individual’s risk for a coronary heart disease or ischemic stroke associated with atherosclerosis, in conjunction with clinical evaluation and patient risk assessment. For more information about the PLAC(R) test visit www.plactest.com. More information about the company may be found at www.diaDexus.com.
diaDexus, Inc.
CONTACT: Christina Andrian of diaDexus, Inc., +1-650-246-6476, orcandrian@diadexus.com; or Jennifer Larson of WeissComm Partners,+1-415-946-1074, or jlarson@weisscommpartners.com, for diaDexus, Inc.
Web site: http://www.diadexus.com/
